-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the morning of April 7, Harbin Pharmaceutical announced that it has entered into a global external licensing agreement with AstraZeneca to develop and commercialize HBM7022
.
It is reported that Hebo Medicine and AstraZeneca reached a cooperation, which made Hebo Medicine jump nearly 60% in early trading
.
According to the announcement, HBM7022 is a novel bispecific antibody produced by Harbin Pharmaceutical's HCAb-based Immune Cell Engager (HBICE) platform
.
The antibody is a bispecific antibody against tumor-associated antigen (Claudin18.
2) and CD3.
By binding to tumor cells and T cells, it strongly activates T cells and kills tumor cells.
It is currently in the preclinical stage
.
According to the agreement, Harbin Pharmaceutical will receive an upfront payment of US$25 million from AstraZeneca, and may receive up to US$325 million after reaching development, regulatory and commercial milestones
.
Companies are also entitled to tiered royalties
.
The cooperation with AstraZeneca is of great significance to Harbin Pharmaceutical, which is a verification of Harbin Pharmaceutical's technology platform and innovation potential
.
Hebo Pharmaceuticals stated that it will take advantage of this opportunity to further strengthen its global cooperation network through innovative cooperation models, and maximize the scientific and commercial value of Hebo Medical's technology platform
.
In addition, some people said that this cooperation will help Harbin Pharmaceutical to accelerate its overseas layout
.
It is understood that accelerating the process of globalization and realizing overseas market layout is an important step in the development of current pharmaceutical companies.
Many domestic pharmaceutical companies are actively reaching authorization agreements with foreign pharmaceutical companies
.
For example, in addition to the licensing cooperation between Harbin Pharmaceutical and AstraZeneca, on April 1, Jinfang Pharmaceutical and SELLAS Life Sciences Group announced that they had reached an exclusive licensing agreement.
Global development and commercialization rights for the molecular inhibitor GFH009 injection outside of Greater China
.
Public information shows that GFH009 is a highly selective small molecule CDK9 inhibitor, which has shown good apoptosis-inducing and anti-proliferative activities in various human cell lines and disease animal models, and can effectively inhibit the growth of various models of tumors.
, and significantly prolong the survival of tumor-bearing animals
.
According to the agreement, SELLAS will pay Jinfang Pharmaceutical a $10 million down payment and technology transfer fees, as well as development milestone payments of up to $48 million based on the development of no more than three indications
.
In addition, Jinfang Pharmaceutical will receive a cumulative sales milestone payment of US$92 million outside of Greater China (including mainland China, Hong Kong, Macau, and Taiwan)
.
Based on GFH009's annual percentage of net sales, SELLAS will also pay Jinfang Pharmaceutical Gradient royalties
.
Fosun Pharma is also a relatively successful case of accelerating overseas market layout through external licensing
.
It is reported that it has licensed FCN-338, Hanquyou, slulimumab and other self-developed blockbuster varieties
.
In February 2022, Henlius and Getz Pharma reached a commercialization authorization cooperation for Handayuan (adalimumab injection), covering 11 emerging markets in Asia, Africa and Europe, further accelerating the company's global commercialization layout
.
In addition, on March 30, Biosion announced the signing of a licensing agreement with Pyxis Oncology
.
Pursuant to the agreement, Pyxis Oncology will receive an exclusive license for the global development and commercialization of BSI-060T, an innovative antibody from Biosyn, excluding Greater China.
Biosyn will receive an upfront payment of US$10 million and will also be eligible to receive the total amount Milestone payments of up to $222.
5 million, and royalties up to a double-digit percentage of sales
.
Industry insiders said that innovative drugs also have to go through price negotiation in China, and the competition among enterprises is fierce, and the product return cycle is short, and returns must be realized from the world
.
Therefore, it is necessary to innovate on the one hand, and globalization on the other to realize value from the international market
.
It is reported that many pharmaceutical companies are now actively strengthening overseas market expansion, among which the realization of external authorization is one of the important ways
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is reported that Hebo Medicine and AstraZeneca reached a cooperation, which made Hebo Medicine jump nearly 60% in early trading
.
According to the announcement, HBM7022 is a novel bispecific antibody produced by Harbin Pharmaceutical's HCAb-based Immune Cell Engager (HBICE) platform
.
The antibody is a bispecific antibody against tumor-associated antigen (Claudin18.
2) and CD3.
By binding to tumor cells and T cells, it strongly activates T cells and kills tumor cells.
It is currently in the preclinical stage
.
According to the agreement, Harbin Pharmaceutical will receive an upfront payment of US$25 million from AstraZeneca, and may receive up to US$325 million after reaching development, regulatory and commercial milestones
.
Companies are also entitled to tiered royalties
.
The cooperation with AstraZeneca is of great significance to Harbin Pharmaceutical, which is a verification of Harbin Pharmaceutical's technology platform and innovation potential
.
Hebo Pharmaceuticals stated that it will take advantage of this opportunity to further strengthen its global cooperation network through innovative cooperation models, and maximize the scientific and commercial value of Hebo Medical's technology platform
.
In addition, some people said that this cooperation will help Harbin Pharmaceutical to accelerate its overseas layout
.
It is understood that accelerating the process of globalization and realizing overseas market layout is an important step in the development of current pharmaceutical companies.
Many domestic pharmaceutical companies are actively reaching authorization agreements with foreign pharmaceutical companies
.
For example, in addition to the licensing cooperation between Harbin Pharmaceutical and AstraZeneca, on April 1, Jinfang Pharmaceutical and SELLAS Life Sciences Group announced that they had reached an exclusive licensing agreement.
Global development and commercialization rights for the molecular inhibitor GFH009 injection outside of Greater China
.
Public information shows that GFH009 is a highly selective small molecule CDK9 inhibitor, which has shown good apoptosis-inducing and anti-proliferative activities in various human cell lines and disease animal models, and can effectively inhibit the growth of various models of tumors.
, and significantly prolong the survival of tumor-bearing animals
.
According to the agreement, SELLAS will pay Jinfang Pharmaceutical a $10 million down payment and technology transfer fees, as well as development milestone payments of up to $48 million based on the development of no more than three indications
.
In addition, Jinfang Pharmaceutical will receive a cumulative sales milestone payment of US$92 million outside of Greater China (including mainland China, Hong Kong, Macau, and Taiwan)
.
Based on GFH009's annual percentage of net sales, SELLAS will also pay Jinfang Pharmaceutical Gradient royalties
.
Fosun Pharma is also a relatively successful case of accelerating overseas market layout through external licensing
.
It is reported that it has licensed FCN-338, Hanquyou, slulimumab and other self-developed blockbuster varieties
.
In February 2022, Henlius and Getz Pharma reached a commercialization authorization cooperation for Handayuan (adalimumab injection), covering 11 emerging markets in Asia, Africa and Europe, further accelerating the company's global commercialization layout
.
In addition, on March 30, Biosion announced the signing of a licensing agreement with Pyxis Oncology
.
Pursuant to the agreement, Pyxis Oncology will receive an exclusive license for the global development and commercialization of BSI-060T, an innovative antibody from Biosyn, excluding Greater China.
Biosyn will receive an upfront payment of US$10 million and will also be eligible to receive the total amount Milestone payments of up to $222.
5 million, and royalties up to a double-digit percentage of sales
.
Industry insiders said that innovative drugs also have to go through price negotiation in China, and the competition among enterprises is fierce, and the product return cycle is short, and returns must be realized from the world
.
Therefore, it is necessary to innovate on the one hand, and globalization on the other to realize value from the international market
.
It is reported that many pharmaceutical companies are now actively strengthening overseas market expansion, among which the realization of external authorization is one of the important ways
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
